Trials / Completed
CompletedNCT05412979
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
A Multicenter, Randomized, Double-Blind, Crossover, Phase 2 Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 490 (actual)
- Sponsor
- Sention Therapeutics, LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
ST-1891-201 is a multicenter, randomized, double-blind, partial crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ST-1891 | ST-1891 |
| DRUG | Levothyroxine | Levothyroxine |
Timeline
- Start date
- 2022-04-29
- Primary completion
- 2023-10-04
- Completion
- 2023-10-04
- First posted
- 2022-06-09
- Last updated
- 2024-08-26
Locations
39 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05412979. Inclusion in this directory is not an endorsement.